Free Trial

Pediatrix Medical Group (MD) Financials

Pediatrix Medical Group logo
$12.14 -0.36 (-2.88%)
As of 10:50 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
Annual Income Statements for Pediatrix Medical Group

Annual Income Statements for Pediatrix Medical Group

This table shows Pediatrix Medical Group's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Net Income / (Loss) Attributable to Common Shareholders
317 336 325 320 269 -1,498 -796 131 66 -60 -99
Consolidated Net Income / (Loss)
317 336 325 320 269 -1,498 -796 131 66 -60 -99
Net Income / (Loss) Continuing Operations
317 336 325 305 122 42 -9.58 108 63 -60 -99
Total Pre-Tax Income
509 540 514 386 166 59 7.15 135 81 -48 -101
Total Operating Income
513 558 572 455 248 172 98 203 173 7.32 -69
Total Gross Profit
2,439 2,780 3,183 3,253 1,723 1,780 1,734 1,911 1,972 1,995 2,013
Total Revenue
2,439 2,780 3,183 3,253 1,723 1,780 1,734 1,911 1,972 1,995 2,013
Operating Revenue
2,439 2,780 3,183 3,253 1,723 1,780 1,734 1,911 1,972 1,995 2,013
Total Cost of Revenue
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses
1,926 2,222 2,611 2,798 1,475 1,608 1,636 1,723 1,799 1,987 2,082
Selling, General & Admin Expense
1,791 2,059 2,404 2,613 1,358 1,425 1,443 1,561 1,615 1,676 1,679
Depreciation Expense
46 64 89 79 24 26 28 32 36 36 32
Other Operating Expenses / (Income)
89 98 118 106 92 96 91 100 122 125 127
Impairment Charge
- - - 0.00 - - - 0.00 0.00 148 178
Restructuring Charge
- - - 0.00 0.00 61 74 22 27 2.22 64
Total Other Income / (Expense), net
-4.38 -18 -58 -69 -82 -113 -91 -68 -91 -56 -33
Interest Expense
8.89 23 63 75 93 119 110 83 97 42 41
Interest & Investment Income
4.51 4.97 5.20 5.34 11 5.96 19 16 5.39 6.40 8.12
Other Income / (Expense), net
- - - - - 0.00 - 0.00 0.00 -20 0.00
Income Tax Expense
191 204 189 80 45 17 17 27 19 12 -2.27
Net Income / (Loss) Discontinued Operations
- - - 15 147 -1,540 -787 23 3.77 0.00 0.00
Net Income / (Loss) Attributable to Noncontrolling Interest
-0.08 -0.63 -0.32 - - 0.00 0.00 -0.03 -0.00 0.00 0.00
Basic Earnings per Share
$3.22 $3.61 $3.52 $3.47 $2.95 ($17.94) ($9.55) $1.54 $0.79 ($0.73) ($1.19)
Weighted Average Basic Shares Outstanding
98.59M 93.08M 92.42M 92.43M 91.10M 83.50M 83.40M 84.83M 83.47M 82.20M 83.33M
Diluted Earnings per Share
$3.18 $3.58 $3.49 $3.45 $2.93 ($17.83) ($9.55) $1.53 $0.79 ($0.73) ($1.19)
Weighted Average Diluted Shares Outstanding
99.89M 93.96M 93.11M 92.96M 91.61M 84.01M 83.40M 85.83M 84.12M 82.20M 83.33M
Weighted Average Basic & Diluted Shares Outstanding
98.50M 93.20M 93.79M 92.30M 91.10M 84.28M 85.63M 86.47M 83.03M 84.12M 85.83M

Quarterly Income Statements for Pediatrix Medical Group

This table shows Pediatrix Medical Group's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Income / (Loss) Attributable to Common Shareholders
31 30 15 28 21 -125 4.10 -153 21 28
Consolidated Net Income / (Loss)
31 30 14 28 21 -124 4.04 -153 19 30
Net Income / (Loss) Continuing Operations
29 24 14 28 21 -124 4.04 -153 19 30
Total Pre-Tax Income
39 28 21 39 31 -139 7.82 -168 25 33
Total Operating Income
47 36 30 48 40 -111 16 -158 34 39
Total Gross Profit
490 514 491 501 507 496 495 504 511 502
Total Revenue
490 514 491 501 507 496 495 504 511 502
Operating Revenue
490 514 491 501 507 496 495 504 511 502
Total Operating Expenses
443 478 461 452 466 608 479 662 477 463
Selling, General & Admin Expense
401 418 421 412 426 417 429 414 423 413
Depreciation Expense
8.96 9.14 8.95 8.95 9.21 9.06 10 8.79 6.25 6.87
Other Operating Expenses / (Income)
32 31 31 31 31 32 31 43 30 24
Restructuring Charge
0.98 20 0.00 0.00 0.00 2.22 8.48 14 19 24
Total Other Income / (Expense), net
-8.53 -8.21 -9.33 -9.55 -9.44 -27 -8.07 -10 -8.59 -5.96
Interest Expense
9.52 9.95 10 11 10 10 11 10 10 9.71
Interest & Investment Income
0.99 1.74 1.06 1.68 0.93 2.72 2.53 0.30 1.53 3.75
Income Tax Expense
10 3.82 6.51 11 9.44 -15 3.79 -15 5.79 2.85
Basic Earnings per Share
$0.37 $0.35 $0.17 $0.34 $0.26 ($1.50) $0.05 ($1.84) $0.23 $0.37
Weighted Average Basic Shares Outstanding
82.13M 83.47M 81.89M 82.40M 82.54M 82.20M 82.86M 83.33M 83.89M 83.33M
Diluted Earnings per Share
$0.37 $0.35 $0.17 $0.34 $0.26 ($1.50) $0.05 ($1.84) $0.23 $0.37
Weighted Average Diluted Shares Outstanding
82.78M 84.12M 82.32M 82.66M 82.95M 82.20M 83.28M 83.33M 84.52M 83.33M
Weighted Average Basic & Diluted Shares Outstanding
83.07M 83.03M 83.76M 83.94M 84.02M 84.12M 84.15M 85.87M 85.88M 85.83M

Annual Cash Flow Statements for Pediatrix Medical Group

This table details how cash moves in and out of Pediatrix Medical Group's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Net Change in Cash & Equivalents
17 3.64 4.13 25 0.33 161 1,016 -736 -378 63 157
Net Cash From Operating Activities
423 369 444 511 314 358 205 77 167 137 207
Net Cash From Continuing Operating Activities
423 369 444 483 59 74 154 114 182 146 217
Net Income / (Loss) Continuing Operations
317 336 325 305 122 42 -9.58 108 63 -60 -99
Consolidated Net Income / (Loss)
317 336 325 320 269 -1,498 -796 131 66 -60 -99
Net Income / (Loss) Discontinued Operations
- - - 15 147 -1,540 -787 23 3.77 0.00 0.00
Depreciation Expense
46 64 89 79 24 26 28 32 36 36 32
Amortization Expense
1.23 1.54 4.82 5.51 4.57 5.67 7.16 4.34 1.77 1.24 0.95
Non-Cash Adjustments To Reconcile Net Income
26 31 31 51 34 40 39 38 73 177 197
Changes in Operating Assets and Liabilities, net
32 -64 -5.66 42 -125 -40 89 -55 9.06 -8.39 86
Net Cash From Discontinued Operating Activities
- - - 28 255 284 51 -37 -15 -8.76 -11
Net Cash From Investing Activities
-504 -848 -821 -577 -143 102 816 -53 -57 -48 -35
Net Cash From Continuing Investing Activities
-504 -848 -821 -553 -85 -50 -58 -55 -57 -48 -35
Purchase of Property, Plant & Equipment
-18 -27 -39 -26 -17 -19 -29 -32 -30 -33 -22
Acquisitions
-479 -819 -762 -531 -65 47 -2.23 -30 -28 -6.67 -8.17
Purchase of Investments
-27 -34 -61 -28 -16 -35 -62 -35 -17 -32 -65
Sale of Property, Plant & Equipment
- - - - - 0.00 1.08 25 1.38 0.81 6.84
Sale and/or Maturity of Investments
21 32 41 25 14 51 33 16 17 23 52
Net Cash From Financing Activities
98 483 382 90 -171 -393 -4.16 -760 -488 -26 -14
Net Cash From Continuing Financing Activities
98 483 382 90 -169 -384 -2.91 -760 0.00 0.00 0.00
Repayment of Debt
-1,218 -2,172 -1,512 -2,704 -2,102 -1,996 -528 -759 -1,882 -495 -248
Repurchase of Common Equity
-488 -235 -62 -70 -302 -145 -8.49 -4.72 -89 -0.92 -1.70
Issuance of Debt
1,755 2,872 1,940 2,846 2,224 1,747 528 0.00 1,480 470 236
Issuance of Common Equity
44 20 22 24 16 11 7.25 6.85 5.40 4.91 3.64
Other Financing Activities, net
5.72 -1.27 -6.50 -5.45 -5.26 -1.39 -1.16 -3.00 -2.92 -4.44 -4.06
Net Cash From Discontinued Financing Activities
- - - -0.61 -1.36 -8.96 -1.25 0.00 0.00 0.00 0.00
Cash Interest Paid
7.32 20 60 74 83 95 110 87 116 42 40
Cash Income Taxes Paid
162 181 176 75 185 86 -28 55 27 31 4.67

Quarterly Cash Flow Statements for Pediatrix Medical Group

This table details how cash moves in and out of Pediatrix Medical Group's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Change in Cash & Equivalents
-5.42 1.16 -3.70 -0.28 15 52 -65 11 84 126
Net Cash From Operating Activities
83 99 -101 89 80 69 -125 107 92 133
Net Cash From Continuing Operating Activities
88 102 -101 93 81 73 -123 109 96 135
Net Income / (Loss) Continuing Operations
29 24 14 28 21 -124 4.04 -153 19 30
Consolidated Net Income / (Loss)
31 30 14 28 21 -124 4.04 -153 19 30
Depreciation Expense
8.96 9.14 8.95 8.95 9.21 9.06 10 8.79 6.25 6.87
Amortization Expense
0.49 0.42 0.39 0.34 0.28 0.22 0.20 0.24 0.26 0.25
Non-Cash Adjustments To Reconcile Net Income
3.32 5.76 2.62 2.62 2.46 170 1.80 194 3.84 -3.06
Changes in Operating Assets and Liabilities, net
47 63 -127 52 48 18 -139 59 66 100
Net Cash From Discontinued Operating Activities
-5.02 -3.61 -0.27 -3.55 -1.18 -3.75 -2.60 -2.39 -3.89 -1.80
Net Cash From Investing Activities
-6.09 -11 -11 -10 -14 -12 -16 -13 -4.34 -1.94
Net Cash From Continuing Investing Activities
- -57 0.00 -22 -14 -12 0.00 -29 -4.34 -1.94
Purchase of Property, Plant & Equipment
-6.95 -9.06 -7.00 -8.13 -9.15 -9.04 -5.33 -6.96 -6.29 -3.44
Purchase of Investments
-1.96 -2.41 -9.55 -8.21 -8.72 -5.42 -17 -23 -14 -10
Sale of Property, Plant & Equipment
0.96 -0.78 0.00 - - 0.69 0.00 - - 4.48
Sale and/or Maturity of Investments
1.85 1.00 6.87 5.95 3.75 6.35 14 17 14 7.17
Net Cash From Financing Activities
-83 -86 109 -79 -51 -4.75 76 -83 -3.07 -4.96
Net Cash From Continuing Financing Activities
-83 401 109 -79 -51 21 76 -83 -3.07 9.52
Repayment of Debt
-261 -241 -107 -285 -100 -3.45 -94 -148 6.22 -12
Repurchase of Common Equity
-21 -1.47 -0.78 -0.01 -0.13 - -0.89 -0.01 -0.16 -0.64
Issuance of Common Equity
1.38 1.18 1.10 1.59 1.19 1.04 0.86 1.15 0.90 0.73
Other Financing Activities, net
-0.91 -0.74 -0.70 -0.70 -0.70 -2.33 -0.69 -0.70 -10 7.37

Annual Balance Sheets for Pediatrix Medical Group

This table presents Pediatrix Medical Group's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Total Assets
3,608 4,547 5,339 5,867 5,937 4,146 3,348 2,723 2,348 2,220 2,153
Total Current Assets
467 528 587 627 660 732 1,549 841 428 483 640
Cash & Equivalents
48 52 56 60 25 108 1,124 387 9.82 73 230
Short-Term Investments
6.04 8.85 11 10 22 75 105 100 93 104 119
Accounts Receivable
352 445 495 504 507 434 242 302 297 272 260
Prepaid Expenses
7.04 9.64 11 16 17 17 17 19 15 14 13
Current Deferred & Refundable Income Taxes
46 - - - - - 0.00 14 0.00 7.57 13
Other Current Assets
7.90 13 14 37 17 12 62 19 13 12 5.09
Plant, Property, & Equipment, net
66 84 103 124 90 73 76 70 73 76 39
Total Noncurrent Assets
3,075 3,936 4,649 5,117 5,187 3,342 1,722 1,812 1,847 1,661 1,474
Goodwill
2,776 3,366 3,845 4,284 4,061 1,480 1,478 1,505 1,532 1,384 1,243
Intangible Assets
198 424 669 640 313 29 27 22 18 21 12
Noncurrent Deferred & Refundable Income Taxes
- - - - 22 87 54 88 106 103 104
Other Noncurrent Operating Assets
37 82 57 112 81 105 163 196 190 152 116
Total Liabilities & Shareholders' Equity
3,608 4,547 5,339 5,867 5,937 4,146 3,348 2,723 2,348 2,220 2,153
Total Liabilities
1,343 2,109 2,579 2,801 2,850 2,647 2,600 1,826 1,456 1,371 1,388
Total Current Liabilities
416 429 449 531 503 542 444 427 427 389 434
Short-Term Debt
10 12 22 1.40 0.25 - - 2.49 15 15 21
Accounts Payable
381 396 408 438 449 411 423 394 374 351 399
Current Deferred & Payable Income Tax Liabilities
25 21 19 92 31 6.04 0.00 11 16 2.16 2.17
Other Current Liabilities
- - - - 0.00 18 21 20 22 21 13
Total Noncurrent Liabilities
926 1,681 2,130 2,269 2,347 2,105 2,156 1,398 1,029 982 954
Long-Term Debt
558 1,263 1,684 1,851 1,974 1,730 1,743 0.00 636 618 597
Noncurrent Deferred & Payable Income Tax Liabilities
160 189 228 148 96 56 62 41 34 34 34
Other Noncurrent Operating Liabilities
208 229 218 270 241 272 352 1,357 359 329 322
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
2,266 2,438 2,761 3,066 3,088 1,499 748 897 892 849 765
Total Preferred & Common Equity
2,265 2,438 2,761 3,066 3,088 1,499 747 896 892 849 765
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
2,265 2,438 2,761 3,066 3,088 1,499 747 896 892 849 765
Common Stock
888 927 975 1,018 994 989 1,030 1,051 984 1,001 1,015
Retained Earnings
1,377 1,510 1,786 2,048 2,094 510 -286 -155 -89 -149 -249
Accumulated Other Comprehensive Income / (Loss)
- - - - - 0.08 3.53 1.32 -3.74 -2.21 -1.07

Quarterly Balance Sheets for Pediatrix Medical Group

This table presents Pediatrix Medical Group's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024
Total Assets
2,332 2,320 2,306 2,326 2,168 1,995 2,077
Total Current Assets
424 409 398 421 427 429 528
Cash & Equivalents
8.67 6.12 5.85 21 8.00 19 104
Short-Term Investments
91 97 98 104 107 114 117
Accounts Receivable
294 279 271 277 284 274 287
Prepaid Expenses
9.66 15 12 11 13 12 10
Current Deferred & Refundable Income Taxes
9.73 - - - 5.19 0.00 1.20
Other Current Assets
9.90 12 10 7.87 9.58 9.94 9.48
Plant, Property, & Equipment, net
72 73 73 75 74 48 42
Total Noncurrent Assets
1,837 1,839 1,834 1,831 1,667 1,518 1,507
Goodwill
1,532 1,532 1,532 1,532 1,393 1,239 1,239
Intangible Assets
20 17 17 15 19 10 13
Noncurrent Deferred & Refundable Income Taxes
98 103 102 103 102 124 119
Other Noncurrent Operating Assets
187 119 184 180 83 145 135
Total Liabilities & Shareholders' Equity
2,332 2,320 2,306 2,326 2,168 1,995 2,077
Total Liabilities
1,473 1,410 1,363 1,358 1,312 1,289 1,344
Total Current Liabilities
352 284 320 350 247 310 373
Short-Term Debt
15 15 15 15 16 18 19
Accounts Payable
306 227 278 303 207 267 333
Current Deferred & Payable Income Tax Liabilities
7.66 22 6.15 11 2.80 6.33 3.32
Other Current Liabilities
23 21 22 22 21 19 17
Total Noncurrent Liabilities
1,122 1,126 1,043 1,008 1,065 979 971
Long-Term Debt
731 114 666 622 80 0.00 0.00
Noncurrent Deferred & Payable Income Tax Liabilities
40 33 38 41 34 31 36
Other Noncurrent Operating Liabilities
351 979 339 345 951 948 936
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
859 910 942 968 856 706 732
Total Preferred & Common Equity
859 910 942 968 856 706 732
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
859 910 942 968 856 706 732
Common Stock
981 988 992 997 1,004 1,007 1,012
Retained Earnings
-119 -75 -47 -25 -145 -298 -279
Accumulated Other Comprehensive Income / (Loss)
-4.10 -3.13 -3.52 -3.52 -2.15 -1.95 -0.21

Annual Metrics and Ratios for Pediatrix Medical Group

This table displays calculated financial ratios and metrics derived from Pediatrix Medical Group's official financial filings.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Growth Metrics
- - - - - - - - - - -
Revenue Growth
13.23% 13.99% 14.50% 2.21% -47.04% 3.29% -2.57% 10.22% 3.18% 1.15% 0.92%
EBITDA Growth
13.84% 11.32% 6.76% -19.00% -48.58% -26.67% -34.24% 79.01% -12.24% -88.23% -243.68%
EBIT Growth
13.46% 8.75% 2.48% -20.43% -45.40% -30.85% -42.87% 106.78% -14.90% -107.34% -441.94%
NOPAT Growth
13.11% 8.45% 4.09% -0.25% -49.59% -32.09% -206.65% 223.21% -18.06% -96.14% -1,038.57%
Net Income Growth
13.08% 5.83% -3.31% -1.30% -16.15% -657.54% 46.82% 116.44% -49.34% -191.07% -64.00%
EPS Growth
14.39% 12.58% -2.51% -1.15% -15.07% -708.53% 46.44% 116.02% -48.37% -192.41% -63.01%
Operating Cash Flow Growth
4.25% -12.76% 20.36% 15.23% -38.65% 14.03% -42.80% -62.50% 117.55% -17.74% 50.43%
Free Cash Flow Firm Growth
-208.28% -333.50% 29.51% 76.42% 851.15% 348.77% -97.31% 1,178.17% -188.48% 115.68% 58.53%
Invested Capital Growth
19.39% 32.12% 20.39% 10.36% -9.95% -65.71% -14.31% -67.34% 249.41% -9.39% -20.74%
Revenue Q/Q Growth
3.53% 3.39% 2.88% -3.70% -47.34% 73.79% 41.00% 4.48% 0.78% -0.86% 0.30%
EBITDA Q/Q Growth
4.05% 2.58% -0.10% -10.67% -44.13% 114.35% 58.31% 16.32% -12.89% -87.15% 80.70%
EBIT Q/Q Growth
3.46% 1.80% -1.41% -8.50% -41.80% 58.25% 91.77% 21.35% -15.62% -108.19% 68.69%
NOPAT Q/Q Growth
3.35% 2.09% -2.64% 18.80% -52.48% 62.32% -467.16% 23.58% -11.90% -95.54% 68.69%
Net Income Q/Q Growth
3.02% 1.25% -4.23% 22.12% -22.03% -3.52% -10.19% 584.42% -21.21% -164.58% 60.97%
EPS Q/Q Growth
2.25% 0.28% -4.90% 22.34% -21.02% -2.59% -12.22% 800.00% -20.20% -165.18% 25.63%
Operating Cash Flow Q/Q Growth
10.33% -16.84% 6.43% 14.48% -12.36% -4.30% -41.83% 271.88% 48.40% -17.65% 44.65%
Free Cash Flow Firm Q/Q Growth
-77.61% 8.64% 1.18% -660.18% 489.25% 52.66% -97.74% 244.09% 7.21% 0.48% -72.02%
Invested Capital Q/Q Growth
2.40% 0.59% 0.16% 3.62% -11.88% -51.24% 384.20% 5.86% -4.30% -11.84% 94.63%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin
22.97% 22.43% 20.92% 16.58% 16.09% 11.43% 7.71% 12.53% 10.65% 1.24% -1.77%
Operating Margin
21.03% 20.07% 17.96% 13.98% 14.42% 9.65% 5.66% 10.62% 8.76% 0.37% -3.41%
EBIT Margin
21.03% 20.07% 17.96% 13.98% 14.42% 9.65% 5.66% 10.62% 8.76% -0.64% -3.41%
Profit (Net Income) Margin
13.01% 12.08% 10.20% 9.85% 15.59% -84.15% -45.93% 6.85% 3.36% -3.03% -4.92%
Tax Burden Percent
62.37% 62.20% 63.18% 83.07% 161.62% -2,547.81% -11,142.81% 96.83% 81.52% 124.92% 97.76%
Interest Burden Percent
99.15% 96.75% 89.87% 84.78% 66.91% 34.23% 7.28% 66.64% 47.12% 381.41% 147.48%
Effective Tax Rate
37.63% 37.80% 36.82% 20.80% 26.89% 28.20% 234.02% 20.14% 23.11% 0.00% 0.00%
Return on Invested Capital (ROIC)
12.82% 11.01% 9.13% 7.93% 4.01% 4.28% -9.62% 19.36% 14.34% 0.37% -4.11%
ROIC Less NNEP Spread (ROIC-NNEP)
11.39% 9.60% 6.43% 5.48% 10.00% -270.72% -282.64% -193.26% -194.61% -12.68% -18.18%
Return on Net Nonoperating Assets (RNNOA)
0.95% 3.27% 3.36% 3.07% 4.72% -69.58% -61.28% -3.44% -6.92% -7.31% -8.16%
Return on Equity (ROE)
13.77% 14.27% 12.49% 11.00% 8.73% -65.30% -70.90% 15.93% 7.42% -6.94% -12.28%
Cash Return on Invested Capital (CROIC)
-4.86% -16.67% -9.37% -1.92% 14.48% 102.14% 5.79% 120.88% -96.66% 10.23% 19.02%
Operating Return on Assets (OROA)
15.51% 13.68% 11.56% 8.12% 4.21% 3.41% 2.62% 6.69% 6.81% -0.56% -3.14%
Return on Assets (ROA)
9.59% 8.23% 6.57% 5.72% 4.55% -29.71% -21.26% 4.31% 2.62% -2.65% -4.53%
Return on Common Equity (ROCE)
13.76% 14.27% 12.49% 11.00% 8.73% -65.30% -70.90% 15.92% 7.42% -6.94% -12.28%
Return on Equity Simple (ROE_SIMPLE)
14.01% 13.77% 11.76% 10.45% 8.70% -99.91% -106.56% 14.61% 7.44% -7.11% -12.95%
Net Operating Profit after Tax (NOPAT)
320 347 361 360 182 123 -132 162 133 5.12 -48
NOPAT Margin
13.12% 12.48% 11.35% 11.07% 10.54% 6.93% -7.59% 8.48% 6.73% 0.26% -2.39%
Net Nonoperating Expense Percent (NNEP)
1.43% 1.41% 2.70% 2.45% -5.99% 275.00% 273.02% 212.63% 208.95% 13.06% 14.07%
Return On Investment Capital (ROIC_SIMPLE)
- - - - - - - - 8.61% 0.35% -3.48%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
73.43% 74.08% 75.52% 80.32% 78.80% 80.08% 83.21% 81.67% 81.88% 84.02% 83.42%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
78.97% 79.93% 82.04% 86.02% 85.58% 90.35% 94.34% 90.14% 91.24% 99.63% 103.41%
Earnings before Interest and Taxes (EBIT)
513 558 572 455 248 172 98 203 173 -13 -69
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
560 624 666 539 277 203 134 239 210 25 -36
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
2.93 2.76 2.26 1.63 0.96 1.56 2.81 2.62 1.38 0.92 1.47
Price to Tangible Book Value (P/TBV)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)
2.72 2.42 1.96 1.54 1.71 1.32 1.21 1.23 0.63 0.39 0.56
Price to Earnings (P/E)
20.92 20.04 19.21 15.62 10.98 0.00 0.00 17.96 18.61 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
4.78% 4.99% 5.21% 6.40% 9.10% 0.00% 0.00% 5.57% 5.37% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
2.61 2.20 1.81 1.41 1.12 2.64 2.07 4.53 1.24 0.95 1.35
Enterprise Value to Revenue (EV/Rev)
2.91 2.84 2.45 2.06 2.78 2.19 1.51 0.98 0.90 0.62 0.69
Enterprise Value to EBITDA (EV/EBITDA)
12.66 12.65 11.72 12.44 17.27 19.13 19.55 7.80 8.49 50.02 0.00
Enterprise Value to EBIT (EV/EBIT)
13.82 14.14 13.65 14.74 19.28 22.65 26.64 9.21 10.32 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
22.16 22.74 21.60 18.62 26.37 31.55 0.00 11.53 13.43 241.38 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
16.78 21.40 17.58 13.11 15.26 10.88 12.78 24.34 10.68 9.01 6.76
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 7.30 1.32 33.04 1.85 0.00 8.82 6.28
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.25 0.52 0.62 0.60 0.64 1.15 2.33 0.00 0.73 0.75 0.81
Long-Term Debt to Equity
0.25 0.52 0.61 0.60 0.64 1.15 2.33 0.00 0.71 0.73 0.78
Financial Leverage
0.08 0.34 0.52 0.56 0.47 0.26 0.22 0.02 0.04 0.58 0.45
Leverage Ratio
1.44 1.73 1.90 1.92 1.92 2.20 3.34 3.69 2.84 2.62 2.71
Compound Leverage Factor
1.42 1.68 1.71 1.63 1.28 0.75 0.24 2.46 1.34 10.01 4.00
Debt to Total Capital
20.07% 34.34% 38.19% 37.66% 39.00% 53.58% 69.97% 0.28% 42.21% 42.72% 44.67%
Short-Term Debt to Total Capital
0.37% 0.32% 0.49% 0.03% 0.01% 0.00% 0.00% 0.28% 0.97% 1.01% 1.49%
Long-Term Debt to Total Capital
19.70% 34.01% 37.70% 37.64% 39.00% 53.58% 69.97% 0.00% 41.25% 41.72% 43.19%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.03% 0.01% 0.00% 0.00% 0.00% 0.00% 0.01% 0.02% 0.00% 0.00% 0.00%
Common Equity to Total Capital
79.90% 65.66% 61.81% 62.34% 61.00% 46.42% 30.02% 99.70% 57.79% 57.28% 55.33%
Debt to EBITDA
1.02 2.04 2.56 3.44 7.12 8.51 13.03 0.01 3.10 25.61 -17.38
Net Debt to EBITDA
0.80 1.85 2.34 3.16 6.63 7.61 3.84 -2.02 2.61 18.42 -7.57
Long-Term Debt to EBITDA
1.00 2.02 2.53 3.43 7.12 8.51 13.03 0.00 3.03 25.01 -16.80
Debt to NOPAT
1.78 3.67 4.72 5.14 10.87 14.03 -13.25 0.02 4.91 123.58 -12.84
Net Debt to NOPAT
1.41 3.32 4.32 4.72 10.12 12.55 -3.91 -2.99 4.13 88.90 -5.60
Long-Term Debt to NOPAT
1.75 3.64 4.66 5.14 10.87 14.03 -13.25 0.00 4.79 120.67 -12.41
Altman Z-Score
4.66 3.42 2.90 2.39 1.58 1.32 1.38 1.82 1.54 1.18 1.27
Noncontrolling Interest Sharing Ratio
0.02% 0.03% 0.01% 0.00% 0.00% 0.00% 0.01% 0.03% 0.01% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
1.12 1.23 1.31 1.18 1.31 1.35 3.49 1.97 1.00 1.24 1.47
Quick Ratio
0.98 1.18 1.25 1.08 1.10 1.14 3.31 1.85 0.94 1.16 1.40
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-121 -526 -370 -87 656 2,945 79 1,012 -895 140 222
Operating Cash Flow to CapEx
2,340.08% 1,361.88% 1,130.24% 1,955.56% 1,832.41% 1,856.41% 738.49% 1,106.20% 589.27% 422.27% 1,360.20%
Free Cash Flow to Firm to Interest Expense
-13.64 -22.74 -5.87 -1.17 7.06 24.76 0.72 12.15 -9.25 3.34 5.46
Operating Cash Flow to Interest Expense
47.54 15.95 7.03 6.86 3.38 3.01 1.85 0.92 1.73 3.26 5.07
Operating Cash Flow Less CapEx to Interest Expense
45.50 14.78 6.41 6.51 3.19 2.85 1.60 0.84 1.43 2.49 4.70
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.74 0.68 0.64 0.58 0.29 0.35 0.46 0.63 0.78 0.87 0.92
Accounts Receivable Turnover
7.65 6.98 6.77 6.51 3.41 3.78 5.13 7.03 6.59 7.01 7.56
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
38.73 37.15 34.10 28.71 16.11 21.82 23.30 26.12 27.50 26.79 35.06
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
47.71 52.32 53.89 56.05 107.05 96.49 71.17 51.92 55.39 52.07 48.26
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
47.71 52.32 53.89 56.05 107.05 96.49 71.17 51.92 55.39 52.07 48.26
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
2,716 3,589 4,320 4,768 4,294 1,472 1,262 412 1,440 1,305 1,034
Invested Capital Turnover
0.98 0.88 0.80 0.72 0.38 0.62 1.27 2.28 2.13 1.45 1.72
Increase / (Decrease) in Invested Capital
441 873 732 448 -475 -2,821 -211 -850 1,028 -135 -271
Enterprise Value (EV)
7,090 7,890 7,802 6,707 4,788 3,891 2,615 1,868 1,783 1,237 1,396
Market Capitalization
6,638 6,739 6,242 5,005 2,951 2,343 2,101 2,352 1,234 781 1,127
Book Value per Share
$22.55 $25.92 $29.48 $32.74 $34.53 $17.78 $8.73 $10.37 $10.73 $10.11 $8.91
Tangible Book Value per Share
($7.07) ($14.39) ($18.72) ($19.83) ($14.39) ($0.11) ($8.85) ($7.29) ($7.93) ($6.62) ($5.70)
Total Capital
2,834 3,713 4,466 4,919 5,062 3,229 2,490 899 1,543 1,482 1,383
Total Debt
569 1,275 1,706 1,853 1,975 1,730 1,743 2.49 651 633 618
Total Long-Term Debt
558 1,263 1,684 1,851 1,974 1,730 1,743 0.00 636 618 597
Net Debt
451 1,151 1,560 1,702 1,837 1,548 514 -485 548 456 269
Capital Expenditures (CapEx)
18 27 39 26 17 19 28 6.94 28 33 15
Debt-free, Cash-free Net Working Capital (DFCFNWC)
7.28 50 93 27 90 7.31 -124 -71 -87 -68 -122
Debt-free Net Working Capital (DFNWC)
61 111 160 97 157 190 1,105 416 16 109 226
Net Working Capital (NWC)
51 99 138 96 157 190 1,105 413 1.01 95 205
Net Nonoperating Expense (NNE)
2.73 11 37 40 -87 1,621 665 31 66 66 51
Net Nonoperating Obligations (NNO)
451 1,151 1,560 1,702 1,206 -27 514 -485 548 456 269
Total Depreciation and Amortization (D&A)
47 66 94 84 29 32 36 36 37 37 33
Debt-free, Cash-free Net Working Capital to Revenue
0.30% 1.82% 2.93% 0.82% 5.23% 0.41% -7.13% -3.74% -4.42% -3.43% -6.08%
Debt-free Net Working Capital to Revenue
2.51% 3.99% 5.03% 2.99% 9.14% 10.66% 63.73% 21.75% 0.81% 5.49% 11.23%
Net Working Capital to Revenue
2.08% 3.56% 4.34% 2.94% 9.12% 10.66% 63.73% 21.62% 0.05% 4.74% 10.21%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
$3.22 $3.61 $3.52 $3.47 $2.95 ($17.94) $0.00 $1.54 $0.79 $0.73 ($1.19)
Adjusted Weighted Average Basic Shares Outstanding
98.59M 93.08M 92.42M 92.43M 91.10M 83.50M 0.00 84.83M 83.47M 82.20M 83.33M
Adjusted Diluted Earnings per Share
$3.18 $3.58 $3.49 $3.45 $2.93 ($17.94) $0.00 $1.53 $0.79 $0.73 ($1.19)
Adjusted Weighted Average Diluted Shares Outstanding
99.89M 93.96M 93.11M 92.96M 91.61M 83.50M 0.00 85.83M 84.12M 82.20M 83.33M
Adjusted Basic & Diluted Earnings per Share
$0.00 $3.61 $3.52 $3.47 $2.95 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
96.08M 93.80M 93.79M 93.80M 87.92M 84.28M 0.00 86.47M 83.03M 84.12M 85.83M
Normalized Net Operating Profit after Tax (NOPAT)
320 347 361 360 182 167 120 186 154 110 122
Normalized NOPAT Margin
13.12% 12.48% 11.35% 11.07% 10.54% 9.39% 6.94% 9.71% 7.80% 5.54% 6.05%
Pre Tax Income Margin
20.85% 19.41% 16.14% 11.85% 9.65% 3.30% 0.41% 7.08% 4.13% -2.42% -5.03%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
57.70 24.14 9.06 6.10 2.67 1.44 0.89 2.44 1.79 -0.30 -1.69
NOPAT to Interest Expense
35.98 15.01 5.72 4.83 1.95 1.04 -1.19 1.95 1.37 0.12 -1.18
EBIT Less CapEx to Interest Expense
55.67 22.97 8.44 5.75 2.49 1.28 0.64 2.35 1.49 -1.07 -2.06
NOPAT Less CapEx to Interest Expense
33.95 13.84 5.10 4.48 1.77 0.87 -1.44 1.86 1.08 -0.65 -1.55
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
153.98% 70.02% 19.05% 21.91% 112.48% -9.70% -1.07% 3.60% 133.44% -1.52% -1.72%

Quarterly Metrics and Ratios for Pediatrix Medical Group

This table displays calculated financial ratios and metrics derived from Pediatrix Medical Group's official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Growth Metrics
- - - - - - - - - -
Revenue Growth
-0.62% 3.07% 1.82% 2.99% 3.41% -3.39% 0.83% 0.74% 0.90% 1.19%
EBITDA Growth
-17.19% -40.54% -18.71% -2.41% -12.43% -324.17% -32.97% -357.33% -18.93% 145.41%
EBIT Growth
-19.40% -47.01% -23.18% -3.30% -15.01% -409.37% -47.10% -425.22% -16.00% 135.24%
NOPAT Growth
-18.49% -39.26% -24.73% -1.58% -20.47% -351.06% -60.22% -413.50% -6.73% 146.04%
Net Income Growth
-0.19% -37.57% 167.03% 4.22% -30.39% -519.05% -71.60% -641.07% -9.12% 124.52%
EPS Growth
2.78% -36.36% 168.00% 6.25% -29.73% -528.57% -70.59% -641.18% -11.54% 124.67%
Operating Cash Flow Growth
36.38% 123.09% -3.52% 8.07% -4.07% -29.83% -24.09% 20.10% 14.89% 92.07%
Free Cash Flow Firm Growth
-36.71% -210.66% 102.78% 105.45% 104.87% 105.73% 659.68% 1,216.49% 1,753.56% 436.26%
Invested Capital Growth
286.52% 249.41% 0.70% -1.74% -1.64% -9.39% -10.55% -61.10% -64.10% -20.74%
Revenue Q/Q Growth
0.80% 4.88% -4.44% 1.95% 1.21% -2.01% -0.27% 1.86% 1.36% -1.72%
EBITDA Q/Q Growth
-4.02% -19.78% -13.61% 46.71% -13.88% -305.37% 125.83% -663.23% 127.13% 15.05%
EBIT Q/Q Growth
-5.52% -23.95% -16.64% 61.44% -16.96% -376.84% 114.25% -1,092.47% 121.45% 16.15%
NOPAT Q/Q Growth
-1.82% -11.51% -33.72% 70.92% -20.66% -379.32% 110.50% -1,447.10% 123.60% 37.89%
Net Income Q/Q Growth
13.24% -3.48% -52.10% 99.08% -24.37% -681.02% 103.25% -3,892.44% 112.70% 56.78%
EPS Q/Q Growth
15.63% -5.41% -51.43% 100.00% -23.53% -676.92% 225.00% -3,780.00% 112.50% 60.87%
Operating Cash Flow Q/Q Growth
1.12% 18.43% -202.26% 188.24% -10.24% -13.37% -280.83% 185.41% -14.13% 44.83%
Free Cash Flow Firm Q/Q Growth
5.26% 7.73% 101.41% 341.41% -15.36% 8.69% -84.17% 664.94% 19.17% -68.55%
Invested Capital Q/Q Growth
-2.69% -4.30% -35.00% 62.34% -2.59% -11.84% 21.99% -29.40% -10.10% 94.63%
Profitability Metrics
- - - - - - - - - -
Gross Margin
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin
11.60% 8.87% 8.02% 11.54% 9.82% -20.59% 5.33% -29.49% 7.89% 9.24%
Operating Margin
9.67% 7.01% 6.12% 9.69% 7.95% -22.46% 3.21% -31.28% 6.62% 7.82%
EBIT Margin
9.67% 7.01% 6.12% 9.69% 7.95% -22.46% 3.21% -31.28% 6.62% 7.82%
Profit (Net Income) Margin
6.27% 5.77% 2.89% 5.65% 4.22% -25.04% 0.82% -30.34% 3.80% 6.07%
Tax Burden Percent
79.08% 106.60% 68.59% 72.62% 69.38% 89.51% 51.57% 91.23% 77.04% 91.45%
Interest Burden Percent
82.00% 77.21% 68.95% 80.31% 76.56% 124.54% 49.23% 106.34% 74.60% 84.82%
Effective Tax Rate
25.87% 13.74% 31.41% 27.38% 30.62% 0.00% 48.43% 0.00% 22.96% 8.55%
Return on Invested Capital (ROIC)
14.82% 12.88% 8.91% 9.16% 7.44% -22.85% 3.73% -41.55% 10.18% 12.31%
ROIC Less NNEP Spread (ROIC-NNEP)
10.17% 8.40% -7.43% 8.07% 6.31% -32.06% -114.83% -60.02% 5.91% 10.81%
Return on Net Nonoperating Assets (RNNOA)
1.13% 0.30% -0.33% 5.77% 4.00% -18.49% -0.46% -16.80% 1.08% 4.85%
Return on Equity (ROE)
15.95% 13.18% 8.59% 14.93% 11.43% -41.34% 3.28% -58.35% 11.26% 17.17%
Cash Return on Invested Capital (CROIC)
-101.87% -96.66% 12.44% 9.73% 9.36% 10.23% 10.60% 73.84% 79.05% 19.02%
Operating Return on Assets (OROA)
7.60% 5.46% 5.20% 8.27% 6.87% -19.61% 2.86% -29.12% 6.03% 7.20%
Return on Assets (ROA)
4.93% 4.49% 2.46% 4.82% 3.65% -21.87% 0.73% -28.26% 3.47% 5.59%
Return on Common Equity (ROCE)
15.95% 13.18% 8.59% 14.93% 11.43% -41.34% 3.28% -58.35% 11.26% 17.17%
Return on Equity Simple (ROE_SIMPLE)
9.80% 0.00% 11.18% 10.92% 9.66% 0.00% -8.24% -35.65% -34.65% 0.00%
Net Operating Profit after Tax (NOPAT)
35 31 21 35 28 -78 8.20 -110 26 36
NOPAT Margin
7.17% 6.05% 4.20% 7.04% 5.52% -15.72% 1.66% -21.89% 5.10% 7.15%
Net Nonoperating Expense Percent (NNEP)
4.65% 4.48% 16.34% 1.09% 1.13% 9.21% 118.56% 18.47% 4.26% 1.50%
Return On Investment Capital (ROIC_SIMPLE)
- 2.01% - - - -5.26% - - - 2.60%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
81.80% 81.27% 85.80% 82.31% 84.05% 83.93% 86.72% 82.17% 82.76% 82.12%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
90.33% 92.99% 93.88% 90.31% 92.05% 122.46% 96.79% 131.28% 93.38% 92.18%
Earnings before Interest and Taxes (EBIT)
47 36 30 48 40 -111 16 -158 34 39
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
57 46 39 58 50 -102 26 -149 40 46
Valuation Ratios
- - - - - - - - - -
Price to Book Value (P/BV)
1.62 1.38 1.36 1.26 1.10 0.92 0.98 0.90 1.36 1.47
Price to Tangible Book Value (P/TBV)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)
0.71 0.63 0.63 0.60 0.53 0.39 0.42 0.32 0.50 0.56
Price to Earnings (P/E)
16.54 18.61 12.10 11.55 11.38 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
6.05% 5.37% 8.27% 8.66% 8.79% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
1.35 1.24 1.35 1.16 1.07 0.95 0.98 0.88 1.49 1.35
Enterprise Value to Revenue (EV/Rev)
1.04 0.90 0.64 0.89 0.78 0.62 0.41 0.26 0.40 0.69
Enterprise Value to EBITDA (EV/EBITDA)
8.45 8.49 6.29 8.85 8.20 50.02 25.95 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
9.96 10.32 7.73 10.91 10.20 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
13.53 13.43 10.31 14.46 13.73 241.38 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
18.12 10.68 7.73 10.39 9.47 9.01 7.29 3.97 5.56 6.76
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 10.89 11.85 11.30 8.82 8.77 0.67 1.00 6.28
Leverage & Solvency
- - - - - - - - - -
Debt to Equity
0.87 0.73 0.14 0.72 0.66 0.75 0.11 0.03 0.03 0.81
Long-Term Debt to Equity
0.85 0.71 0.13 0.71 0.64 0.73 0.09 0.00 0.00 0.78
Financial Leverage
0.11 0.04 0.04 0.71 0.63 0.58 0.00 0.28 0.18 0.45
Leverage Ratio
2.92 2.84 2.61 2.62 2.55 2.62 2.54 2.61 2.59 2.71
Compound Leverage Factor
2.40 2.19 1.80 2.10 1.95 3.27 1.25 2.77 1.93 2.30
Debt to Total Capital
46.49% 42.21% 12.41% 41.96% 39.67% 42.72% 10.12% 2.45% 2.56% 44.67%
Short-Term Debt to Total Capital
0.93% 0.97% 1.44% 0.92% 0.93% 1.01% 1.72% 2.45% 2.56% 1.49%
Long-Term Debt to Total Capital
45.56% 41.25% 10.98% 41.04% 38.74% 41.72% 8.40% 0.00% 0.00% 43.19%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
53.51% 57.79% 87.59% 58.04% 60.33% 57.28% 89.88% 97.55% 97.44% 55.33%
Debt to EBITDA
3.09 3.10 0.64 3.41 3.31 25.61 3.04 -0.10 -0.10 -17.38
Net Debt to EBITDA
2.68 2.61 0.13 2.89 2.66 18.42 -0.60 0.66 1.09 -7.57
Long-Term Debt to EBITDA
3.03 3.03 0.57 3.34 3.23 25.01 2.52 0.00 0.00 -16.80
Debt to NOPAT
4.95 4.91 1.05 5.58 5.54 123.58 -20.17 -0.12 -0.13 -12.84
Net Debt to NOPAT
4.29 4.13 0.21 4.72 4.45 88.90 3.99 0.77 1.31 -5.60
Long-Term Debt to NOPAT
4.85 4.79 0.93 5.45 5.41 120.67 -16.74 0.00 0.00 -12.41
Altman Z-Score
1.44 1.35 1.44 1.47 1.41 1.03 1.34 0.90 1.37 1.44
Noncontrolling Interest Sharing Ratio
0.01% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - -
Current Ratio
1.20 1.00 1.44 1.24 1.20 1.24 1.72 1.38 1.42 1.47
Quick Ratio
1.12 0.94 1.34 1.17 1.15 1.16 1.61 1.31 1.36 1.40
Cash Flow Metrics
- - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-1,080 -997 14 62 53 57 107 818 975 306
Operating Cash Flow to CapEx
1,392.78% 1,003.62% -1,441.88% 1,095.24% 873.26% 829.04% -2,349.46% 1,536.21% 1,460.06% 0.00%
Free Cash Flow to Firm to Interest Expense
-113.51 -100.15 1.35 5.53 5.07 5.67 10.09 79.34 96.25 31.56
Operating Cash Flow to Interest Expense
8.76 9.92 -9.71 7.93 7.71 6.87 -11.81 10.38 9.07 13.70
Operating Cash Flow Less CapEx to Interest Expense
8.13 8.93 -10.39 7.21 6.82 6.04 -12.32 9.70 8.45 13.80
Efficiency Ratios
- - - - - - - - - -
Asset Turnover
0.79 0.78 0.85 0.85 0.86 0.87 0.89 0.93 0.91 0.92
Accounts Receivable Turnover
7.03 6.59 6.64 6.90 7.04 7.01 7.11 7.35 7.11 7.56
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
27.14 27.50 27.25 27.43 27.41 26.79 27.14 33.04 34.29 35.06
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
51.89 55.39 54.95 52.87 51.86 52.07 51.36 49.67 51.31 48.26
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
51.89 55.39 54.95 52.87 51.86 52.07 51.36 49.67 51.31 48.26
Capital & Investment Metrics
- - - - - - - - - -
Invested Capital
1,505 1,440 936 1,519 1,480 1,305 837 591 531 1,034
Invested Capital Turnover
2.07 2.13 2.12 1.30 1.35 1.45 2.25 1.90 2.00 1.72
Increase / (Decrease) in Invested Capital
1,115 1,028 6.53 -27 -25 -135 -99 -928 -949 -271
Enterprise Value (EV)
2,039 1,783 1,264 1,767 1,579 1,237 824 520 794 1,396
Market Capitalization
1,393 1,234 1,238 1,190 1,067 781 843 635 995 1,127
Book Value per Share
$10.18 $10.73 $10.96 $11.25 $11.53 $10.11 $10.33 $8.40 $8.53 $8.91
Tangible Book Value per Share
($8.21) ($7.93) ($7.71) ($7.24) ($6.90) ($6.62) ($6.71) ($6.45) ($6.05) ($5.70)
Total Capital
1,605 1,543 1,039 1,624 1,605 1,482 953 724 752 1,383
Total Debt
746 651 129 681 637 633 96 18 19 618
Total Long-Term Debt
731 636 114 666 622 618 80 0.00 0.00 597
Net Debt
646 548 26 577 512 456 -19 -115 -201 269
Capital Expenditures (CapEx)
5.98 9.83 7.00 8.13 9.15 8.35 5.33 6.96 6.29 -1.04
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-13 -87 36 -12 -40 -68 80 3.59 -46 -122
Debt-free Net Working Capital (DFNWC)
87 16 139 92 85 109 196 137 174 226
Net Working Capital (NWC)
72 1.01 124 77 70 95 179 119 155 205
Net Nonoperating Expense (NNE)
4.40 1.43 6.40 6.94 6.55 46 4.16 43 6.62 5.45
Net Nonoperating Obligations (NNO)
646 548 26 577 512 456 -19 -115 -201 269
Total Depreciation and Amortization (D&A)
9.45 9.56 9.35 9.29 9.49 9.29 11 9.03 6.52 7.12
Debt-free, Cash-free Net Working Capital to Revenue
-0.67% -4.42% 1.84% -0.60% -1.97% -3.43% 4.01% 0.18% -2.29% -6.08%
Debt-free Net Working Capital to Revenue
4.44% 0.81% 7.03% 4.63% 4.23% 5.49% 9.79% 6.83% 8.69% 11.23%
Net Working Capital to Revenue
3.68% 0.05% 6.28% 3.88% 3.48% 4.74% 8.97% 5.95% 7.73% 10.21%
Earnings Adjustments
- - - - - - - - - -
Adjusted Basic Earnings per Share
$0.37 $0.35 $0.17 $0.34 $0.26 ($1.50) $0.05 ($1.84) $0.23 $0.37
Adjusted Weighted Average Basic Shares Outstanding
82.13M 83.47M 81.89M 82.40M 82.54M 82.20M 82.86M 83.33M 83.89M 83.33M
Adjusted Diluted Earnings per Share
$0.37 $0.35 $0.17 $0.34 $0.26 ($1.50) $0.05 ($1.84) $0.23 $0.37
Adjusted Weighted Average Diluted Shares Outstanding
82.78M 84.12M 82.32M 82.66M 82.95M 82.20M 83.28M 83.33M 84.52M 83.33M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
83.07M 83.03M 83.76M 83.94M 84.02M 84.12M 84.15M 85.87M 85.88M 85.83M
Normalized Net Operating Profit after Tax (NOPAT)
36 48 21 35 28 -76 13 27 40 58
Normalized NOPAT Margin
7.32% 9.34% 4.20% 7.04% 5.52% -15.41% 2.54% 5.26% 7.90% 11.46%
Pre Tax Income Margin
7.93% 5.41% 4.22% 7.78% 6.09% -27.97% 1.58% -33.26% 4.94% 6.63%
Debt Service Ratios
- - - - - - - - - -
EBIT to Interest Expense
4.98 3.62 2.89 4.32 3.88 -11.06 1.50 -15.30 3.34 4.05
NOPAT to Interest Expense
3.69 3.12 1.98 3.14 2.69 -7.74 0.77 -10.71 2.57 3.70
EBIT Less CapEx to Interest Expense
4.35 2.63 2.22 3.59 3.00 -11.89 1.00 -15.98 2.72 4.15
NOPAT Less CapEx to Interest Expense
3.06 2.14 1.31 2.41 1.81 -8.57 0.27 -11.39 1.95 3.81
Payout Ratios
- - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
103.40% 133.44% 86.62% 23.07% 2.55% -1.52% -1.46% -0.41% -0.42% -1.72%

Frequently Asked Questions About Pediatrix Medical Group's Financials

When does Pediatrix Medical Group's financial year end?

According to the most recent income statement we have on file, Pediatrix Medical Group's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Pediatrix Medical Group's net income changed over the last 10 years?

Pediatrix Medical Group's net income appears to be on an upward trend, with a most recent value of -$99.07 million in 2024, falling from $317.20 million in 2014. The previous period was -$60.41 million in 2023.

What is Pediatrix Medical Group's operating income?
Pediatrix Medical Group's total operating income in 2024 was -$68.71 million, based on the following breakdown:
  • Total Gross Profit: $2.01 billion
  • Total Operating Expenses: $2.08 billion
How has Pediatrix Medical Group revenue changed over the last 10 years?

Over the last 10 years, Pediatrix Medical Group's total revenue changed from $2.44 billion in 2014 to $2.01 billion in 2024, a change of -17.5%.

How much debt does Pediatrix Medical Group have?

Pediatrix Medical Group's total liabilities were at $1.39 billion at the end of 2024, a 1.2% increase from 2023, and a 3.4% increase since 2014.

How much cash does Pediatrix Medical Group have?

In the past 10 years, Pediatrix Medical Group's cash and equivalents has ranged from $9.82 million in 2022 to $1.12 billion in 2020, and is currently $229.94 million as of their latest financial filing in 2024.

How has Pediatrix Medical Group's book value per share changed over the last 10 years?

Over the last 10 years, Pediatrix Medical Group's book value per share changed from 22.55 in 2014 to 8.91 in 2024, a change of -60.5%.



This page (NYSE:MD) was last updated on 4/25/2025 by MarketBeat.com Staff
From Our Partners